PureTech Announces Breakthrough in AML Treatment at ASH Annual Meeting PureTech, a leading biotechnology company, presented groundbreaking data on their LYT-200 antibody in the treatment of acute myeloid leukemia (AML) at the 67th Annual American Society of Hematology (ASH) Annual Meeting. The data revealed a remarkable >30% complete response rate in combination therapy for relapsed/refractory […]